Telomir Pharmaceuticals Inc TELO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Trading Information
- Previous Close Price
- $0.78
- Day Range
- $0.78–0.79
- 52-Week Range
- $0.78–1.58
- Bid/Ask
- $0.78 / $0.85
- Shares Outstanding
- 73.68M
- Market Cap
- $57.84M
- Volume/Avg
- 4,412 / 88,623
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
Valuation
Metric | TELO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.66 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | TELO |
|---|---|
Quick Ratio | 15.55 |
Current Ratio | 16.14 |
Interest Coverage | −2,102.65 |
Quick Ratio
TELO
Profitability
Metric | TELO |
|---|---|
Return on Assets (Normalized) | −92.78% |
Return on Equity (Normalized) | −106.11% |
Return on Invested Capital (Normalized) | −110.63% |
Return on Assets
TELO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%%^lCY^ | LOCK|?B$$% | $138B | |||
| Moderna Inc MRNA | LOCK|fnRFR$w | LOCK|gV | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|bc$qZKB | LOCK|XGQ&H | $93B | |||
| argenx SE ADR ARGX | LOCK|?RGx^n< | LOCK|n^y | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|HBnC&KC | LOCK|?X | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%m$M%LD | LOCK|tV^!K | $30B | |||
| Incyte Corp INCY | LOCK|FC@@%km | LOCK|M^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|^XJ&pZZ | LOCK|m% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|f?!^xCq | LOCK|CyZ<X | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|jBs>#@! | LOCK|KQ< | $15B |
United States